These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9554821)

  • 1. Phosphate-binding capacities of calcium and aluminum formulations.
    Lau AH; Kuk JM; Franson KL
    Int J Artif Organs; 1998 Jan; 21(1):19-22. PubMed ID: 9554821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of pH on in vitro disintegration of phosphate binders.
    Stamatakis MK; Alderman JM; Meyer-Stout PJ
    Am J Kidney Dis; 1998 Nov; 32(5):808-12. PubMed ID: 9820451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative phosphate binders in dialysis patients: calcium carbonate.
    Slatopolsky E; Weerts C; Stokes T; Windus D; Delmez J
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):35-41. PubMed ID: 3602677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
    Savica V; Calò LA; Monardo P; Santoro D; Bellinghieri G
    Nephrol Dial Transplant; 2006 Aug; 21(8):2065-8. PubMed ID: 16766546
    [No Abstract]   [Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral phosphate binders: phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in rats.
    Yamaguchi T; Baxter JG; Maebashi N; Asano T
    Ren Fail; 1999 Sep; 21(5):453-68. PubMed ID: 10516989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.
    Slatopolsky E; Weerts C; Lopez-Hilker S; Norwood K; Zink M; Windus D; Delmez J
    N Engl J Med; 1986 Jul; 315(3):157-61. PubMed ID: 3724805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium carbonate 1250 mg/1260 mg: an effective phosphate binder.
    Taylor JE; Henderson IS; Stewart WK; Mactier RA
    Scott Med J; 1990 Apr; 35(2):45-7. PubMed ID: 2374904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phosphate binder up to date].
    Shigematsu T; Sakaguchi T; Orita H
    Clin Calcium; 2007 May; 17(5):772-8. PubMed ID: 17471009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo.
    Yaguchi A; Yonekubo S; Maruyama I; Tatemichi S; Maruyama K; Kobayashi M
    Drug Res (Stuttg); 2016 May; 66(5):262-9. PubMed ID: 26761712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphate binders for control of phosphate retention in chronic renal failure.
    Loghman-Adham M
    Pediatr Nephrol; 1999 Oct; 13(8):701-8. PubMed ID: 10502131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal osteodystrophy and aluminum bone disease in CAPD patients.
    Gokal R
    Clin Nephrol; 1988; 30 Suppl 1():S64-7. PubMed ID: 3052962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder].
    Koiwa F; Sato Y
    Clin Calcium; 2009 Feb; 19(2):198-204. PubMed ID: 19182359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding and managing hyperphosphatemia in patients with chronic renal disease.
    Malluche HH; Monier-Faugere MC
    Clin Nephrol; 1999 Nov; 52(5):267-77. PubMed ID: 10584989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of oral bases on aluminum absorption.
    Mauro LS; Kuhl DA; Kirchhoff JR; Mauro VF; Hamilton RW
    Am J Ther; 2001; 8(1):21-5. PubMed ID: 11304654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preference study: calcium acetate tablets versus gelcaps in hemodialysis patients.
    Kaplan MR; Stashenko CL; Bledsoe AL; McGowan J
    Nephrol Nurs J; 2002 Aug; 29(4):363-5. PubMed ID: 12224369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The radiographic spectrum of renal osteodystrophy.
    Molpus WM; Pritchard RS; Walker CW; Fitzrandolph RL
    Am Fam Physician; 1991 Jan; 43(1):151-8. PubMed ID: 1986484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.